Fig. 3: Protein O-GlcNAcylation of CDC27 is inhibited in OSMI-1-treated MM cells. | Acta Pharmacologica Sinica

Fig. 3: Protein O-GlcNAcylation of CDC27 is inhibited in OSMI-1-treated MM cells.

From: Inhibition of CDC27 O-GlcNAcylation coordinates the antitumor efficacy in multiple myeloma through the autophagy-lysosome pathway

Fig. 3

a Flowchart shows the strategy of immunoprecipitation (IP) and LC-MS/MS analysis. b Coomassie blue staining verifies the protein ladders in IgG control, RL2-precipitated lysis, and input samples. The red box indicates the sample used for LC-MS/MS analysis. c Table shows the downregulated peptides and their related functions according to the LC-MS/MS analysis. d Plots show the secondary mass spectrum analysis of the CDC27 peptide in vehicle- or OSMI-1-treated MM.1S cells. e Representative images showing the binding of CDC27 with OGT, O-GlcNAcylation in vehicle- or OSMI-1-treated MM.1S cells by the Co-IP assay. f Bar chart shows the viability of MM.1S cells treated with Ctrl or siCDC27 in the absence or presence of Thiamet G. Representative flow images and bar charts show the cell cycle analysis g and apoptosis analysis h in MM.1S cells treated with Ctrl or siCDC27 in the absence or presence of Thiamet G by flow cytometry. Data are obtained from two independent experiments in e and three independent experiments in f–h. The data are presented as the means ± SD. One-way ANOVA with Tukey’s multiple comparison test was used in f–h. ns: not significant. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Back to article page